Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMC NASDAQ:DKNG NASDAQ:EIDX NASDAQ:HMSY NYSE:NCLH NASDAQ:REAL NASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMCAMC Entertainment$2.95-1.8%$2.97$2.45▼$5.56$1.51B1.3510.89 million shs10.49 million shsDKNGDraftKings$43.29-1.3%$45.07$29.64▼$53.61$21.49B1.7310.04 million shs6.80 million shsEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/AHMSYHMS$36.98$36.92$23.12▼$37.22$3.28B0.811.44 million shsN/ANCLHNorwegian Cruise Line$25.57+0.7%$24.63$14.21▼$29.29$11.56B2.1914.41 million shs7.61 million shsREALRealReal$10.55-1.8%$7.43$2.71▼$11.38$1.22B2.53.48 million shs2.42 million shsREGNRegeneron Pharmaceuticals$567.84-4.7%$568.27$476.49▼$1,080.00$60.18B0.351.10 million shs1.06 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMCAMC Entertainment-0.83%+2.58%+1.36%-0.67%-37.29%DKNGDraftKings+0.90%+2.36%-7.08%+2.41%+11.61%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%HMSYHMS0.00%0.00%0.00%0.00%0.00%NCLHNorwegian Cruise Line+0.68%-2.30%+1.66%+31.25%+21.69%REALRealReal-1.38%+7.40%+41.13%+120.99%+231.48%REGNRegeneron Pharmaceuticals+0.62%+4.03%+1.05%+14.06%-47.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMCAMC Entertainment$2.95-1.8%$2.97$2.45▼$5.56$1.51B1.3510.89 million shs10.49 million shsDKNGDraftKings$43.29-1.3%$45.07$29.64▼$53.61$21.49B1.7310.04 million shs6.80 million shsEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/AHMSYHMS$36.98$36.92$23.12▼$37.22$3.28B0.811.44 million shsN/ANCLHNorwegian Cruise Line$25.57+0.7%$24.63$14.21▼$29.29$11.56B2.1914.41 million shs7.61 million shsREALRealReal$10.55-1.8%$7.43$2.71▼$11.38$1.22B2.53.48 million shs2.42 million shsREGNRegeneron Pharmaceuticals$567.84-4.7%$568.27$476.49▼$1,080.00$60.18B0.351.10 million shs1.06 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMCAMC Entertainment-0.83%+2.58%+1.36%-0.67%-37.29%DKNGDraftKings+0.90%+2.36%-7.08%+2.41%+11.61%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%HMSYHMS0.00%0.00%0.00%0.00%0.00%NCLHNorwegian Cruise Line+0.68%-2.30%+1.66%+31.25%+21.69%REALRealReal-1.38%+7.40%+41.13%+120.99%+231.48%REGNRegeneron Pharmaceuticals+0.62%+4.03%+1.05%+14.06%-47.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMCAMC Entertainment 2.00Hold$3.3312.90% UpsideDKNGDraftKings 2.96Moderate Buy$55.1227.31% UpsideEIDXEidos Therapeutics 0.00N/AN/AN/AHMSYHMS 0.00N/AN/AN/ANCLHNorwegian Cruise Line 2.78Moderate Buy$27.808.73% UpsideREALRealReal 2.80Moderate Buy$11.7010.92% UpsideREGNRegeneron Pharmaceuticals 2.82Moderate Buy$817.6744.00% UpsideCurrent Analyst Ratings BreakdownLatest REGN, DKNG, EIDX, NCLH, HMSY, AMC, and REAL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/19/2025NCLHNorwegian Cruise LineTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $31.009/16/2025NCLHNorwegian Cruise LineZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/15/2025REALRealRealB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $12.009/11/2025NCLHNorwegian Cruise LineStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $37.009/10/2025REALRealRealBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.009/2/2025REGNRegeneron PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy8/27/2025NCLHNorwegian Cruise LineTigress FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$36.00 ➝ $38.008/27/2025REGNRegeneron PharmaceuticalsSanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$753.00 ➝ $781.008/27/2025REGNRegeneron PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$813.00 ➝ $831.008/26/2025NCLHNorwegian Cruise LineUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$23.00 ➝ $27.008/21/2025DKNGDraftKingsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$54.00(Data available from 9/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMCAMC Entertainment$4.64B0.33N/AN/A($4.25) per share-0.69DKNGDraftKings$4.77B4.51N/AN/A$2.07 per share20.91EIDXEidos Therapeutics$26.69M177.99N/AN/A$4.57 per share26.74HMSYHMS$626.40M5.23$1.68 per share22.06$9.70 per share3.81NCLHNorwegian Cruise Line$9.48B1.22$4.19 per share6.10$3.24 per share7.89REALRealReal$600.48M2.02N/AN/A($3.71) per share-2.84REGNRegeneron Pharmaceuticals$14.20B4.24$43.85 per share12.95$268.50 per share2.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMCAMC Entertainment-$352.60M-$0.89N/AN/AN/A-7.39%N/A-4.07%11/5/2025 (Estimated)DKNGDraftKings-$507.29M-$0.65N/A28.301.03-5.63%-30.06%-6.80%11/6/2025 (Estimated)EIDXEidos Therapeutics-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/AHMSYHMS$87.22M$1.1560.6130.813.048.51%8.86%6.18%N/ANCLHNorwegian Cruise Line$910.26M$1.4517.6313.971.127.52%59.88%4.02%10/30/2025 (Estimated)REALRealReal-$134.20M-$1.06N/A∞N/A-5.55%N/A-8.90%11/3/2025 (Estimated)REGNRegeneron Pharmaceuticals$4.41B$39.6814.3114.941.9831.37%15.06%11.77%10/30/2025 (Estimated)Latest REGN, DKNG, EIDX, NCLH, HMSY, AMC, and REAL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025DKNGDraftKings$0.16$0.30+$0.14$0.30$1.39 billion$1.51 billion8/7/2025Q2 2025REALRealReal-$0.15-$0.13+$0.02-$0.13$159.17 million$165.19 million8/1/2025Q2 2025REGNRegeneron Pharmaceuticals$8.43$12.89+$4.46$12.81$3.30 billion$3.68 billion7/31/2025Q2 2025NCLHNorwegian Cruise Line$0.52$0.51-$0.01$0.07$2.55 billion$2.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMCAMC EntertainmentN/AN/AN/AN/AN/ADKNGDraftKingsN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AHMSYHMSN/AN/AN/AN/AN/ANCLHNorwegian Cruise LineN/AN/AN/AN/AN/AREALRealRealN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$3.520.62%N/A8.87%N/ALatest REGN, DKNG, EIDX, NCLH, HMSY, AMC, and REAL DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/1/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%8/18/20258/18/20259/3/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMCAMC EntertainmentN/A0.440.44DKNGDraftKings1.821.341.34EIDXEidos Therapeutics0.1411.1011.10HMSYHMS0.264.714.71NCLHNorwegian Cruise Line8.050.180.16REALRealRealN/A0.800.66REGNRegeneron Pharmaceuticals0.094.603.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMCAMC Entertainment28.80%DKNGDraftKings37.70%EIDXEidos Therapeutics31.40%HMSYHMS95.83%NCLHNorwegian Cruise Line69.58%REALRealReal64.73%REGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipAMCAMC Entertainment0.32%DKNGDraftKings47.08%EIDXEidos Therapeutics70.10%HMSYHMS2.70%NCLHNorwegian Cruise Line0.41%REALRealReal9.00%REGNRegeneron Pharmaceuticals7.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMCAMC Entertainment33,382512.94 million511.30 millionOptionableDKNGDraftKings5,100496.47 million262.73 millionOptionableEIDXEidos Therapeutics7038.87 millionN/ANot OptionableHMSYHMS3,10088.64 millionN/AOptionableNCLHNorwegian Cruise Line41,700451.94 million450.08 millionOptionableREALRealReal3,011115.24 million104.87 millionNot OptionableREGNRegeneron Pharmaceuticals15,106105.99 million98.55 millionOptionableREGN, DKNG, EIDX, NCLH, HMSY, AMC, and REAL HeadlinesRecent News About These CompaniesRegeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down - Here's Why2 hours ago | marketbeat.comEaton Financial Holdings Company LLC Takes $494,000 Position in Regeneron Pharmaceuticals, Inc. $REGNSeptember 23 at 7:18 AM | marketbeat.comSNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EUSeptember 22 at 1:06 PM | zacks.comRegeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Founders Capital Management LLCSeptember 22 at 7:39 AM | marketbeat.comClear Harbor Asset Management LLC Boosts Position in Regeneron Pharmaceuticals, Inc. $REGNSeptember 22 at 5:55 AM | marketbeat.comExchange Traded Concepts LLC Boosts Position in Regeneron Pharmaceuticals, Inc. $REGNSeptember 22 at 3:49 AM | marketbeat.comPress Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionSeptember 21 at 12:30 AM | globenewswire.comDupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP OpinionSeptember 21 at 12:29 AM | globenewswire.comRegeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Avanza Fonder ABSeptember 21 at 7:01 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Diversified Trust CoSeptember 21 at 4:53 AM | marketbeat.comAssenagon Asset Management S.A. Lowers Position in Regeneron Pharmaceuticals, Inc. $REGNSeptember 20 at 6:23 AM | marketbeat.comLivforsakringsbolaget Skandia Omsesidigt Trims Stake in Regeneron Pharmaceuticals, Inc. $REGNSeptember 20 at 5:57 AM | marketbeat.com77,592 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Kingstone Capital Partners Texas LLCSeptember 20 at 5:57 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sumitomo Mitsui DS Asset Management Company LtdSeptember 20 at 4:09 AM | marketbeat.comProcyon Advisors LLC Sells 5,942 Shares of Regeneron Pharmaceuticals, Inc. $REGNSeptember 20 at 3:53 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of "Moderate Buy" from BrokeragesSeptember 20 at 2:43 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Sees Significant Growth in Short InterestSeptember 20 at 2:40 AM | americanbankingnews.comShort Interest in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Increases By 20.4%September 19, 2025 | marketbeat.comRegeneron donates ebola treatment for use in countries at risk of outbreaksSeptember 19, 2025 | msn.comCan Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?September 19, 2025 | msn.comCan Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?September 19, 2025 | investors.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Take Profits Now: 3 Overbought Stocks Primed for a PullbackBy Dan Schmidt | August 25, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025Football Season Is Here and DraftKings Stock Is SurgingBy Jordan Chussler | September 14, 2025REGN, DKNG, EIDX, NCLH, HMSY, AMC, and REAL Company DescriptionsAMC Entertainment NYSE:AMC$2.94 -0.06 (-1.83%) Closing price 03:59 PM EasternExtended Trading$2.94 0.00 (0.00%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AMC Entertainment Holdings, Inc., through its subsidiaries, engages in the theatrical exhibition business. It owns, operates, or has interests in theatres in the United States and Europe. The company was founded in 1920 and is headquartered in Leawood, Kansas.DraftKings NASDAQ:DKNG$43.29 -0.55 (-1.25%) Closing price 03:59 PM EasternExtended Trading$43.32 +0.03 (+0.07%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DraftKings Inc. operates as a digital sports entertainment and gaming company in the United States and internationally. It provides online sports betting and casino, daily fantasy sports, media, and other consumer products, as well as retails sportsbooks. The company also engages in the design and development of sports betting and casino gaming software for online and retail sportsbooks, and iGaming operators. In addition, it offers DraftKings marketplace, a digital collectibles ecosystem designed for mainstream accessibility that offers curated NFT drops and supports secondary-market transactions. The company is headquartered in Boston, Massachusetts.Eidos Therapeutics NASDAQ:EIDXEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.HMS NASDAQ:HMSYHMS Holdings Corp., through its subsidiaries, provides cost containment solutions in the United States healthcare marketplace. The company offers coordination of benefits services to government and commercial healthcare payers to ensure that the correct party pays the claim; and population management solutions that provide risk-bearing organizations with intelligence across their member populations to identify risks, and enhance patient engagement and outcomes, as well as payment integrity, care management and consumer engagement, and analytical solutions. It serves state Medicaid programs, commercial health plans, federal government health agencies, government and private employers, children's health insurance program, and other healthcare payers, as well as a subcontractor. The company was founded in 1974 and is headquartered in Irving, Texas.Norwegian Cruise Line NYSE:NCLH$25.57 +0.18 (+0.71%) Closing price 03:59 PM EasternExtended Trading$25.56 0.00 (-0.02%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Norwegian Cruise Line Holdings Ltd., together with its subsidiaries, operates as a cruise company in North America, Europe, the Asia-Pacific, and internationally. The company operates through the Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises brands. It offers itineraries ranging from three days to a 180-days calling on various ports, including Scandinavia, Northern Europe, the Mediterranean, the Greek Isles, Alaska, Canada and New England, Hawaii, Asia, Tahiti and the South Pacific, Australia and New Zealand, Africa, India, South America, the Panama Canal, and the Caribbean. It distributes its products through retail/travel advisor and onboard cruise sales channels, as well as meetings, incentives, and charters. Norwegian Cruise Line Holdings Ltd. was founded in 1966 and is based in Miami, Florida.RealReal NASDAQ:REAL$10.55 -0.19 (-1.79%) Closing price 03:59 PM EasternExtended Trading$10.68 +0.14 (+1.30%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The RealReal, Inc. operates an online marketplace for resale luxury goods in the United State. The company offers various product categories, including women's fashion, men's fashion, jewelry, and watches. It primarily sells products through online marketplace and retail stores. The company was incorporated in 2011 and is headquartered in San Francisco, California.Regeneron Pharmaceuticals NASDAQ:REGN$567.84 -27.84 (-4.67%) Closing price 03:59 PM EasternExtended Trading$571.88 +4.04 (+0.71%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Amprius Technologies: Anatomy of a Textbook, Raging Bull Market Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
